Antibody-dependent cell-mediated cytotoxicity against Epstein-Barr virus membrane antigen in African Burkitt's lymphoma

Serial samples of sera from patients with African Burkitt's lymphoma were tested for antibody against Epstein-Barr virus (EBV)-specific membrane antigen (MA) by the antibody-dependent cell-mediated cytotoxicity assay (ADCC). Titers of patients in the long-term survivor group were generally high...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 24; no. 5; p. 567
Main Authors Granlund, D J, Nkrumah, F, Perkins, I V, Biggar, R J, Levine, P H, Fuccillo, D A
Format Journal Article
LanguageEnglish
Published United States 15.11.1979
Subjects
Antibodies, Viral - analysis
Antibodies, Viral - immunology
Antibody-Dependent Cell Cytotoxicity
Antigens, Viral - immunology
Burkitt Lymphoma - immunology
Burkitt Lymphoma - microbiology
Burkitt Lymphoma - mortality
Herpesvirus 4, Human - immunology
Humans
Remission, Spontaneous
Online AccessGet more information

Cover

More Information
Summary:Serial samples of sera from patients with African Burkitt's lymphoma were tested for antibody against Epstein-Barr virus (EBV)-specific membrane antigen (MA) by the antibody-dependent cell-mediated cytotoxicity assay (ADCC). Titers of patients in the long-term survivor group were generally higher than those found in the sera of patients in the short-term survivor group. Although ADCC titers to EBV-MA were not useful in predicting which patients would relapse there was a definite relationship between ADCC titer and prognosis. The individual differences in ADCC titers in patients in remission may explain the variability of responses that have been reported in studies on serotherapy with remission plasma.
ISSN:0020-7136
DOI:10.1002/ijc.2910240508